SCHEMBL11981072

SCHEMBL11981072

CC(C)c1ccc(CO)c(CO)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.43
PTGS1 P23219 1/20 0.43
CACNA1C Q13936 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HIF1A Q16665 2/20 0.42
ALOX12 P18054 2/20 0.42
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
LMNA P02545 2/20 0.40
RNASEH1 O60930 1/20 0.39
TBK1 Q9UHD2 1/20 0.38
TYR P14679 2/20 0.38
CYP2D6 P10635 2/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KCNH2 Q12809 1/20 0.38
ADRB2 P07550 3/20 0.38
TSHR P16473 2/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24116084 0.85 CYP1A2 (0.47) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL9686320 0.83 ACE2 (0.42) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL10053119 0.83 PTGS1 (0.50) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL9685093 0.83 PTGS1 (0.55) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL607135 0.83 ACE2 (0.42) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL10215349 0.83 ADRB2 (0.54) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL12591789 0.81 GAA (0.41) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL6124194 0.81 TRPA1 (0.39) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL12414657 0.81 PTGS1 (0.39) TRPA1PTGS1CACNA1CALDH1A1HIF1A
SCHEMBL1437611 0.81 SLC5A1 (0.42) TRPA1PTGS1CACNA1CALDH1A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383825-B2 Kinase inhibitors ALLERGAN, INC. (US) 2013-02-26 US disclosed
US-20120207810-A1 Kinase Inhibitors SPADA LON T (US) 2012-08-16 US disclosed
US-20110263611-A1 Kinase Inhibitors ALLERGAN, INC. 2011-10-27 US disclosed
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263611-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 TRPA1 3006/4885PTGS1 635/4885CACNA1C 4553/4885
US-20120207810-A1 Kinase Inhibitors PTK2, MAP3K6, MAP3K20 TRPA1 3006/4885PTGS1 635/4885CACNA1C 4553/4885
US-20110166144-A1 Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same DPYD, TYMP, DHFR TRPA1 4120/4885PTGS1 3149/4885CACNA1C 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.